Related Experiment Videos
Sudden cardiac death: still more questions than answers
1Texas Arrhythmia Institute, Houston, USA.
Insights
Sudden cardiac death mechanisms are complex, not solely linked to coronary artery blockages. Hyperlipidemia-associated inflammation, not just atherosclerosis, may drive fatal heart arrhythmias.
Area of Science:
- Cardiology
- Molecular Biology
- Pathophysiology
Background:
- Sudden cardiac death (SCD) is a leading cause of mortality in industrialized nations, often linked to ventricular tachyarrhythmias in coronary heart disease patients.
- The precise mechanisms connecting coronary atherosclerosis to SCD remain incompletely understood, with varying reported incidences of acute thrombotic coronary occlusions in autopsy studies.
- Implantable cardioverter-defibrillator data suggest acute myocardial infarction rarely follows ventricular tachyarrhythmias, challenging the sole occlusion theory.
Discussion:
- Cellular hypertrophy, intraventricular hypertension, cardiomyopathy, and myocarditis are implicated in arrhythmogenesis, with experimental evidence linking hypertrophy changes to ventricular tachyarrhythmia inducibility.
- Atherogenic hyperlipidemias trigger systemic inflammation, characterized by leukocytosis and upregulation of proinflammatory-prothrombotic mediators like platelet-activating factor and cytokines.
- Diurnal patterns of these mediators correlate with circadian rhythms in coronary morbidity and mortality, suggesting a temporal link.
Key Insights:
- The study challenges the exclusive role of acute coronary occlusion in fatal arrhythmias, highlighting alternative arrhythmogenic pathways.
- Hyperlipidemia-induced systemic inflammation and associated mediators are identified as significant contributors to arrhythmogenesis.
- Specific upregulated mediators demonstrate direct arrhythmogenic effects, providing crucial insights into the molecular basis of SCD.
Outlook:
- Understanding the role of hyperlipidemia-associated inflammatory factors opens new avenues for antiarrhythmic drug development.
- Targeting molecular pathways involved in inflammation and prothrombotic mediator regulation may offer novel therapeutic strategies for preventing SCD.
- Further research into the interplay between metabolic factors, inflammation, and cardiac electrophysiology is warranted to elucidate SCD mechanisms.
Abstract:
Sudden cardiac death is the leading cause of death in industrialized countries. It is most frequently due to ventricular tachyarrhythmias occurring in the presence of coronary heart disease, but mechanisms linking sudden death to coronary atherosclerosis are still unclear. In autopsy studies of sudden death patients, the incidence of acute thrombotic coronary occlusions has varied between 4 and 74%. In over 600 consecutive patients with implantable cardioverter-defibrillators, we observed that appropriate shocks for electrogram-verified ventricular tachyarrhythmias was only very rarely followed by signs of acute myocardial infarction (< 3% of cases), not supporting the coronary occlusion theory of fatal arrhythmias. Cellular hypertrophy compensating for cell loss due to ischemia, intraventricular hypertension, cardiomyopathy, and myocarditis might play a role in arrhythmogenesis as evidenced by the fact that experimental induction and regression of hypertrophy are paralleled by changes in the inducibility of ventricular tachyarrhythmias. Atherogenic hyperlipidemias are associated with a systemic inflammatory response manifested by leukocytosis (lymphocytosis) and complex upregulations of proinflammatory-prothrombotic mediators, such as platelet-activating factor, cytokines, and hemostasis factors. The diurnal regulation of these mediators parallels circadian rhythms of coronary morbidity and mortality. Some upregulated mediators have been shown to exert direct arrhythmogenic effects. The potential contribution of hyperlipidemia-associated inflammatory factors to arrhythmogenesis is important, because it opens new molecular targets for antiarrhythmic drug design.